Three key subsidiaries of British financial services group IG have posted improved profit figures for fiscal year 2025 (FY25), marking a recovery from the mixed results reported a year earlier. The results also align with a nearly 25% jump in net profit for the entire publicly listed group (LSE: IGG), which reached £380 million.
IG Subsidiaries Post Profit Gains In FY25
IG Markets Limited, the group's main over-the-counter derivatives business, saw profit jump to £131.2 million from £102.5 million the previous year. The company's net trading revenue climbed to £384.9 million, up from £343.0 million in fiscal 2024.
IG Index Limited, which offers financial spread betting to UK customers, generated profits of £92.7 million in fiscal 2025, compared to £73.0 million the year before. Net trading revenue reached £228.3 million, up from £211.7 million.
The performance also represents a turnaround from 2023, when both IG Markets and IG Index had reported declining profits due to what management called "inflationary pressures, higher interest rates, increased market volatility , and a decline in global equity prices."
The third entity, IG Trading and Investments Limited, which handles stock trading and investment products after being spun off from IG Markets in 2022, continued its growth trajectory too. Profit after tax hit £21.9 million versus £20.7 million in the prior year, while revenue increased to £27.2 million from £20.4 million.
IG Group UK Subsidiaries - Financial Performance Comparison
Metric | IG Markets Limited | IG Index Limited | IG Trading and Investments Limited |
Net Trading Revenue | |||
FY25 | £384.9m | £228.3m | £27.2m |
FY24 | £343.0m | £211.7m | £20.4m |
Change | +£41.9m (+12.2%) | +£16.6m (+7.8%) | +£6.8m (+33.3%) |
Operating Profit | |||
FY25 | £140.5m | £127.2m | £23.8m |
FY24 | £106.1m | £102.3m | £20.5m |
Change | +£34.4m (+32.4%) | +£24.9m (+24.3%) | +£3.3m (+16.1%) |
Profit After Tax | |||
FY25 | £131.2m | £92.7m | £21.9m |
FY24 | £102.5m | £73.0m | £20.7m |
Change | +£28.7m (+28.0%) | +£19.7m (+27.0%) | +£1.2m (+5.8%) |
All three companies paid substantial dividends to their parent company Market Data Limited during the year. IG Markets distributed £121.4 million, IG Index paid out £114.6 million, and IG Trading and Investments returned £29.1 million.
Results Align with the Group’s Overall Performance
The performance across IG's three main UK subsidiaries aligns with the group-level results during fiscal 2025. IG Group's consolidated results showed total revenue of £1.075 billion and net trading revenue of £942.8 million, representing 9% and 12% growth, respectively.
The subsidiary-level results supported the group's performance relative to market expectations. Analysts had projected total revenue between £1.03-1.05 billion, while IG reported figures at the higher end of these estimates.
Net profit increased 24% to £380.4 million at the group level, which reflects the operational changes implemented at the subsidiary level, including cost management initiatives and restructuring efforts.
Active customers increased 137% to 820,000, reflecting the implementation of growth strategies observed at the subsidiary level, including IG Trading and Investments' expansion into stock trading and investment products.
“I am pleased that we are getting closer to our customers and increasing product velocity, which is translating into stronger customer acquisition,” said Breon Corcoran, CEO of IG Group.
New Offering And Regulatory Scrutiny
The results come after IG Group implemented cost-cutting measures in 2023, including reducing its workforce by about 300 employees globally - roughly 10% of staff. The company had targeted annual cost savings of £50 million through these restructuring efforts.
IG Markets noted in its filing that it began offering cryptocurrency derivatives in May 2025 through a partnership with an external provider, expanding its product range as digital assets gain mainstream acceptance.
Despite the improved performance, the companies face ongoing regulatory scrutiny. IG Markets disclosed it's involved in a class action lawsuit in Australia related to OTC derivative sales to retail clients between May 2017 and August 2023, though the case remains at an early stage.
